期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤的治疗进展 被引量：3

Recent advances in therapy of multiple myeloma
下载PDF
导出
摘要 多发性骨髓瘤是一种浆细胞恶性增殖性疾病,其特征是骨髓微环境中恶性浆细胞克隆性增生,血液或尿中存在单克隆蛋白,并伴随器官功能障碍.多发性骨髓瘤大约占肿瘤性疾病的1％以及血液系统恶性肿瘤的13％.近年来,造血干细胞移植以及药物（如沙利度胺、来那度胺和硼替佐米）的应用已延长了患者的总生存时间.本文对多发性骨髓瘤患者在临床上不同治疗阶段的治疗方案进展综述如下.
作者 李弹弹 马杰 闫春艳 付雪 李凤月 侯新珺 刘林湘
机构地区 郑州大学第一附属医院血液内科 青岛市中心医院职业病科 新安县人民医院血液科
出处 《河南医学研究》 CAS 2014年第1期152-154,共3页 Henan Medical Research
关键词 多发性骨髓瘤 治疗方案 血液系统恶性肿瘤 恶性增殖性疾病 造血干细胞移植 器官功能障碍 克隆性增生 骨髓微环境
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Cavo M,Tacchetti P,Patriarca F. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamthasone as induction therapy before,and consolidation therapy after,double autologous stem-cell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study[J].{H}LANCET,2010,(9758):2075-2085.
  • 2Harousseau J L,Attal M,Avet-Loiseau H. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-0l phase Ⅲ trial[J].{H}Journal of Clinical Oncology,2010,(30):4621-4629.
  • 3Sonneveld P,Schmidt-Wolf I G,van der Holt B. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma:results of the randomized phase Ⅲ HOVON-65/GMMG-HD4 trial[J].{H}Journal of Clinical Oncology,2012,(24):2946-2955.
  • 4Cavo M,Zamagni E,Tosi P. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiplemyeloma[J].{H}Blood,2005,(1):35-39.
  • 5Harousseau J L,Attal M,Avet-Loiseau H. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phase Ⅲ1 trial[J].{H}Journal of Clinical Oncology,2010,(30):4621-4629.
  • 6Sellner L,Heiss C,Benner A. Autologous retransplantation for patients with recurrent multiple myeloma:a single-center experience with 200 patients[J].{H}CANCER,2013,(13):2438-2446.
  • 7Orlowski R Z,Nagler A,Sonneveld P. Randomized phase Ⅲ study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:combination therapy improves time to progression[J].{H}Journal of Clinical Oncology,2007,(25):3892-3901.
  • 8姚程,刘峰,姜振宇,康丽花.VAD、M_2和MP化疗方案治疗多发性骨髓瘤的疗效评价[J].吉林大学学报（医学版）,2007,33(1):167-169. 被引量：6
  • 9Dimopoulos M A,Eleutherakis-Papaiakovou V. Adverse effects of thalidomideadm inistration in patients with meoplastic diseases[J].{H}American Journal of Medicine,2004,(7):508-515.
  • 10García-Sanz R,Gonzá1ez-Porras J R,Hernández J M. The oral combination of thalidomide,cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma[J].{H}LEUKEMIA,2004,(4):856-863.

二级参考文献5

  • 1孙步彤,刁建东,卢振霞,张秀梅,孙延霞,关勇.63例多发性骨髓瘤患者的死因分析[J].吉林大学学报（医学版）,2006,32(3):479-479. 被引量：2
  • 2Kumar A, Loughran T, Alsina M, et aI. Mangagement of multiple myeloma: a systematic review and critical appraisal of published studies [J]. Lancet Oncol, 2000, 43 (4): 293-299.
  • 3Sonneveld P, Segeren CM. Changing concepts in MM: from conventional chemotherapy to high-dose treatment [J] .European J Cancer, 2003, 39: 9-18.
  • 4Saunders G, Overview of drug therapy for multiple myeloma [J]. J Oncol Pharm Praet, 2005, 11 (3): 83-100.
  • 5Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients [J]. Blood, 2002, 99 (6):3163-3168.

共引文献11

同被引文献31

引证文献3

二级引证文献15

河南医学研究
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部